ArticleWomen's health (London, England)2016
Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
Article in Women's health (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Financial Literacy, Financial Education, and Cancer Screening Behavior: Evidence from Japan.International journal of environmental research and public health · 2022Article
- Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis.Diagnostics (Basel, Switzerland) · 2020Article
- Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.Molecular biology reports · 2019Article
- Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers.Carcinogenesis · 2018Article
- Ten Important Considerations for Ovarian Cancer Screening.Diagnostics (Basel, Switzerland) · 2017Review
- Complications from Surgeries Related to Ovarian Cancer Screening.Diagnostics (Basel, Switzerland) · 2017Article
- Subtypes of Ovarian Cancer and Ovarian Cancer Screening.Diagnostics (Basel, Switzerland) · 2017Review
- Serum CA125, CA199 and CEA Combined Detection for Epithelial Ovarian Cancer Diagnosis: A Meta-analysis.Open medicine (Warsaw, Poland) · 2017Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effects on survival in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was reported in The Lancet, and demonstrate that reductions in disease-specific mortality in this randomized control trial (RCT) indicate that ovarian cancer screening works. The UKCTOCS was large enough for sufficient accrual and follow-up, using two intervention arms: MMS (a multimodal strategy using the biomarker Ca125 combined with ultrasound as a secondary test) and USS (ultrasound alone) compared against a no-screen control group. MMS and USS performed similarly, showing a statistically significant reduction in mortality that increased with follow-up surveillance (8% reduction in years 0-7 vs 28% in years 7-14). The data led to the estimate that 641 screens are needed to prevent one ovarian cancer death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.